Compare Dr. Reddy's Laboratories Ltd Common Stock (RDY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dr. Reddy's Laboratories Ltd Common Stock vs Thomson Reuters Corp — how do they compare? Dr. Reddy's Laboratories Ltd Common Stock trades at $12.98 (market cap $10.61B), while Thomson Reuters Corp trades at $109.17 (market cap $45.71B). The key difference: Thomson Reuters Corp is far larger — about 4.3× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Thomson Reuters Corp pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Dr. Reddy's Laboratories Ltd Common Stock for 0 Days and Thomson Reuters Corp for 63 Days on average.
| RDY | TRI | |
|---|---|---|
Market Cap | $10.61B | $45.71B |
Volume | 3,738,869 | 1,278,997 |
Sector | Health | Industrials |
52-Week High | $15.38 | $163.45 |
52-Week Low | $11.38 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $10.51B | $48.32B |
Dividend Yield | 0.65% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) trades at $108.00, up 2.72% on the day, near its R3 resistance level of $108. The stock shows a bullish technical trend with strong moving average signals, though the RSI-6 indicates overbought conditions. Fundamentally, TRI reported Q2 2026 EPS of $0.99, beating expectations, with revenue growth projected to $7.8B in 2026 and a net income margin of 21.22%. Recent strategic moves include divesting its Global Print business to focus on technology and AI-driven services, supported by positive analyst sentiment.
The outlook for TRI is positive, driven by recurring revenue strength and AI expansion, with a consensus price target of $128.60 implying ~19% upside. Risks include execution of tech transitions, competitive pressures, and cybersecurity incidents noted in September 2026. Institutional buying and a majority buy rating from analysts reinforce confidence, but investors should monitor earnings delivery and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dr. Reddy's Laboratories Ltd Common Stock
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
